Bremelanotide
Also known as: Bremelanotide, Bremelanotide acetate, PT-141, PT141, Vyleesi
Source Bremelanotide at Peptiology
Save 10% with code PEPTI-BOSSRABBIT-10
Tapping Shop Now & Save 10% copies your 10% off code PEPTI-BOSSRABBIT-10 to your clipboard. Paste it at the Peptiology checkout to claim the discount.
Summary
Bremelanotide (brand name Vyleesi, code PT-141) is a synthetic cyclic heptapeptide that activates MC4R to treat acquired, generalized hypoactive sexual desire disorder (HSDD) in premenopausal women; administered via subcutaneous injection.
Mechanism of Action
Selective agonist of melanocortin receptors MC4R (and MC3R), enhancing sexual arousal pathways in the central nervous system
Routes of Administration
Goals & Uses
- Melanocortin-related skin tanningDermatology / CosmeticLow
- Male sexual dysfunction / erectile dysfunctionSexual HealthLow
- Erectile dysfunctionSexual HealthModerate
- Female sexual arousal disorderSexual DysfunctionModerate
- Hypoactive sexual desire disorderFemale Sexual DysfunctionHigh
- Hypoactive Sexual Desire Disorder (HSDD) treatmentSexual DysfunctionHigh
- Increased sexual desire/libidoSexual HealthHigh
Contraindications
- Known cardiovascular diseaseCardiovascularHigh
- Hypersensitivity to bremelanotide or excipientsAllergic/immunologicHigh
- PregnancyPopulationHighPotential fetal risk or insufficient safety data
- Hypersensitivity to bremelanotide or any excipientsAllergyHigh
- Use in postmenopausal womenEndocrine/hormonalModerate
- Uncontrolled hypertensionCardiovascularModerate
Adverse Effects
- HypertensionCardiovascularUncommonHigh blood pressure
- Injection site reactionsLocalCommon
- HeadacheNeurologicCommonPain in the head or upper neck
- Transient hypertensionCardiovascularCommon
- FlushingVascularCommonWarmth and redness of the skin
- NauseaGastrointestinalCommonFeeling of sickness or urge to vomit
- Injection site erythemaLocalCommonRedness at the injection site
- Hyperpigmentation (focal)DermatologicUncommon
Drug Interactions
- Antihypertensive agentsModerate
- Other sexual dysfunction agents (e.g., sildenafil)Low
- Indomethacin and NSAIDsLow
- NaltrexoneModerate
Population Constraints
- Severe renal impairmentOrgan ImpairmentRelative
- Pediatric patientsAgeAbsolute
- MenSexRelative
- Lactating womenReproductiveAbsolute
- Premenopausal women onlyAge/reproductive StatusAbsolute
- Severe hepatic impairmentOrgan ImpairmentRelative
Regulatory Status
- European UnionUnapprovedSubmitted but not authorized
- United StatesApprovedApproved: Hypoactive sexual desire disorder in premenopausal womenMarketed as Vyleesi
- United KingdomUnapprovedNot licensed
Approved by FDA in 2019 (Vyleesi) for HSDD in premenopausal women; not approved in EU or UK.
Evidence & Sources
No sources recorded yet.
Frequently Asked Questions
What is Bremelanotide?
Bremelanotide (brand name Vyleesi, code PT-141) is a synthetic cyclic heptapeptide that activates MC4R to treat acquired, generalized hypoactive sexual desire disorder (HSDD) in premenopausal women; administered via subcutaneous injection.
What is Bremelanotide used for?
Bremelanotide is educationally associated with: Melanocortin-related skin tanning, Male sexual dysfunction / erectile dysfunction, Erectile dysfunction, Female sexual arousal disorder, Hypoactive sexual desire disorder, Hypoactive Sexual Desire Disorder (HSDD) treatment, Increased sexual desire/libido. Educational only — not medical advice.
How is Bremelanotide administered?
Recorded routes of administration: Subcutaneous.
What are the potential side effects of Bremelanotide?
Reported adverse effects include: Hypertension, Injection site reactions, Headache, Transient hypertension, Flushing, Nausea, Injection site erythema, Hyperpigmentation (focal). This list is not exhaustive — consult a qualified clinician.
Who should avoid Bremelanotide?
Recorded contraindications: Known cardiovascular disease, Hypersensitivity to bremelanotide or excipients, Pregnancy, Hypersensitivity to bremelanotide or any excipients, Use in postmenopausal women, Uncontrolled hypertension. Consult a qualified clinician before use.